id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0950-0006,FDA,FDA-2014-E-0950,"Determination of Regulatory Review Period for Purposes of Patent
Extension; TECFIDERA",Notice,Determinations,2017-10-05T04:00:00Z,2017,10,2017-10-05T04:00:00Z,2017-12-05T04:59:59Z,2017-10-05T14:46:21Z,2017-21435,0,0,0900006482ba0190
FDA-2014-E-0950-0005,FDA,FDA-2014-E-0950,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-06T04:00:00Z,2017,6,2017-06-06T04:00:00Z,,2017-06-06T13:20:21Z,,0,0,0900006482696b72